CONSOLIDATED RESULTS FOR ANNOUNCEMENT TO THE MARKET

For the half year ended 31 December 2010

Ellex Medical Lasers Limited ACN 007 702 927

This results announcement is to be read in conjunction with the statutory financial statements attached to this announcement.

Consolidated Results

Consolidated Nesdits				
Revenues from ordinary activities	down	12%	То	\$A'000 22,372
Consolidated results Earnings before interest, tax, depreciation and amortisation (EBITDA)	down	39%	to	1,737
Profit for the period, before tax	down	63%	to	635
Profit from ordinary activities after tax	down	57%	to	530
Net profit for the period attributable to members	down	57%	to	518
Dividends (distributions)	Amount per security			ed amount per security
Final Dividend				-
Interim Dividend	Nil		Nil	
Previous corresponding period	Nil			Nil
Record date for determining entitlements to the dividend	cord date for determining entitlements to the dividend NOT APPLICABLE			
Record date for determining entitlements to the dividend	nd NOT APPLICABLE			

OTHER INFORMATION

For the half year ended 31 December 2010

Ellex Medical Lasers Limited ACN 007 702 927

Net Tangible Assets per Security	Half Year ended 31 December 2010	Half Year ended 31 December 2009
Net tangible asset backing per ordinary security* (excludes value attributable to goodwill, other intangible assets, deferred tax asset, capitalised development expenditure and related deferred grant income)	\$0.23	\$0.22

Dividends

Date the dividend (distribution) is payable

NOT APPLICABLE

Record date to determine entitlements to the dividend (distribution)

NOT APPLICABLE

If it is a final dividend, has it been declared?

NOT APPLICABLE

Amount per security

Amount per security			
	Amount per security	Franked amount per security at 30%	Amount per security of foreign source
		tax	dividend
Final dividend:			
Current year	0.00 ¢	0.00 ¢	0.00 ¢
Previous year	0.00 ¢	0.00 ¢	0.00 ¢
Interim dividend:			
Current year	0.00 ¢	0.00 ¢	0.00 ¢
Previous year	0.00 ¢	0.00 ¢	0.00 ¢

Ellex Medical Lasers Limited ACN 007 702 927 Report for the half-year ended 31 December 2010

Contents	Page
Directors' report	2
Auditor's independence declaration	3
Directors' declaration	4
Consolidated statement of comprehensive income	5
Consolidated statement of financial position	6
Consolidated statement of changes in equity	7
Consolidated statement of cash flows	8
Notes to the Consolidated financial statements	9
Independent auditor's review report	11
Corporate Directory	13

Directors' report

The directors of Ellex Medical Lasers Limited (The Company) submit herewith the financial report of Ellex Medical Lasers Limited and its subsidiaries (the group) for the half-year ended 31 December 2010. In order to comply with the provisions of the Corporations Act 2001, the directors report as follows:

The names of the directors of the company during or since the end of the half-year are:

Name

Mr V Previn Chairman

Mr A Sundich
Professor J Marshall
Mr M Plunkett
Non-Executive Director
Executive Director

Mr G Canala Non-Executive Director and Company Secretary

Principal Activities

The principal activities of the company during the course of the financial period were the manufacture and sale of ophthalmic equipment.

There were no significant changes in the nature of the activities of the company during the period.

Review of operations

Ellex Medical Lasers Limited (Ellex) generated a Net Profit After Tax of \$530 thousand for the half-year ended 31 December 2010 (2009: a Net Profit After Tax of \$1,229 thousand) on revenue of \$22,372 thousand (2009: \$25,481 thousand).

Distributors

Sales in the Distributor area were down 8% to \$5,999 thousand. The uncertainty in many financial markets and the relatively strong Australian dollar has led to a weakening in demand for capital equipment.

Direct

The delay in purchasing capital equipment by the end customer, due to the global economic conditions in major markets, has caused a 14% decrease in sales to \$16,356 thousand over the prior comparable period. New initiatives are being implemented to help stimulate demand in this market, including launching new third party products into these distribution channels.

Auditor's independence declaration

The auditor's independence declaration is included on page 3 of the half-year report.

Rounding of amounts

The company is a company of the kind referred to in ASIC Class Order 98/100 and in accordance with that Class Order amounts in the directors' report and the half-year financial report are rounded off to the nearest thousand dollars, unless otherwise indicated.

Signed in accordance with a resolution of directors made pursuant to s.306 (3) of the Corporations Act 2001.

On behalf of the Directors

Victor Previn Director



Level 1, 67 Greenhill Rd Wayville SA 5034 GPO Box 1270 Adelaide SA 5001

T 61 8 8372 6666 F 61 8 8372 6677 E info.sa@au.gt.com W www.grantthomton.com.au

AUDITOR'S INDEPENDENCE DECLARATION TO THE DIRECTORS OF ELLEX MEDICAL LASERS LIMITED

In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of Ellex Medical Lasers Limited for the half-year ended 31 December 2010, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
- b no contraventions of any applicable code of professional conduct in relation to the review.

GRANT THORNTON AUDIT PTY LTD

Grant Tlanston.

Chartered Accountants

S J Gray

Director – Audit & Assurance Services

Directors' declaration

The directors declare that:

- (a) in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
- (b) the financial statements and notes thereto are in accordance with the Corporations Act 2001, including compliance with Accounting Standard 134: Interim Financial Reporting and giving a true and fair view of the financial position as at 31 December 2010 and performance of the consolidated entity for the half-year ended on that date.

Signed in accordance with a resolution of the directors made pursuant to s.303 (5) of the Corporations Act 2001.

On behalf of the Directors

Victor Previn
Director

Consolidated statement of comprehensive income for the half-year ended 31 December 2010

Consolidated Group

	Half-year ended 31 Dec 2010 \$'000	Half-year ended 31 Dec 2009 \$'000
Revenue	22,372	25,481
Other income / (expenses)	125	441
Changes in inventories of finished goods and work in progress	568	(1,094)
Raw materials and consumables used	(11,278)	(10,503)
Employee benefits expense	(6,860)	(8,052)
Depreciation and amortisation expense Legal costs	(913) (25)	(919) (60)
Advertising and marketing expense	(716)	(916)
Finance costs	(189)	(204)
Product development raw materials and consumables used	(123)	(60)
Mark-To-Market unrealised foreign exchange (loss) / gain	-	31
Other expenses	(2,326)	(2,410)
Profit before tax	635	1,735
Income tax (expense)	(105)	(506)
Profit for the period	530	1,229
Other comprehensive income	_	
Exchange differences on translating foreign operations	(1,303)	(977)
		252
Total comprehensive income for the period	(773)	252
Profit attributable to:		
Equity holders of the parent	518 12	1,197
Non-controlling interest	12	32
	530	1,229
Total comprehensive income attributable to:		
Equity holders of the parent	(785)	220
Non-controlling interest	12	32
	(773)	252
	_	
Earnings per share:		
From continuing operations:	0.00	1.41
Basic (cents per share) Diluted (cents per share)	0.62 0.62	1.41
Diluted (cents per share)	0.02	1,41

Consolidated statement of financial position as at 31 December 2010

Consolidated Group

Current assets 31 December 2010 30 June 2010 Cash and cash equivalents 3,403 3,220 Trade and other receivables 11,234 13,017 Inventories 16,784 17,099 Current tax assets 24 26 Other assets 742 284 Total current assets 32,187 34,210 Non-current assets 257 295 Property, plant and equipment 2,866 2,995 Deferred tax assets 7,373 7,473 Other intangible assets 7,373 7,473 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total sasets 5,376 5,903 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 2,99 603 Borrowings 1,184 1,654 Provisions 2,18 232			
Cash and cash equivalents 3,403 3,220 Trade and other receivables 11,234 13,017 Inventories 16,784 17,099 Current tax assets 24 26 Other assets 742 848 Total current assets 32,187 34,210 Non-current assets 257 295 Property, plant and equipment 2,866 2,995 Property, plant and equipment 2,866 2,995 Deferred tax assets 7,373 7,473 Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total assets 17,251 17,368 Current liabilities 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,863 7,814 Provisions 1,911 1,941 Other liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 1,755 2,130		2010	2010
Trade and other receivables 11,234 13,017 Inventories 16,784 17,099 Current tax assets 24 26 Other assets 742 848 Total current assets 32,187 34,210 Non-current assets 257 295 Property, plant and equipment 2,866 2,995 Deferred tax assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 49,438 51,578 Trade and other payables 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 15,269 16,26	Current assets		
Inventories 16,784 17,099 Current tax assets 24 26 Other assets 742 848 Total current assets 32,187 34,210 Non-current assets 257 295 Trade and other receivables 2,866 2,995 Deferred tax assets 7,373 7,473 Other intangible assets 7,20 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 2,44 To	Cash and cash equivalents	3,403	3,220
Current tax assets 24 26 Other assets 742 848 Total current assets 32,187 34,210 Non-current assets 257 295 Property, plant and equipment 2,866 2,995 Deferred tax assets 7,273 7,473 Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 353 244 Total non-current liabilities 353 244 Total iabilities 1,184 1,654 Non-current liabilities 1,755 2,130	Trade and other receivables	11,234	13,017
Other assets 742 848 Total current assets 32,187 34,210 Non-current assets 32,187 34,210 Property, plant and equipment 2,866 2,995 Deferred tax assets 7,373 7,473 Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 2,18 232 Other liabilities 3,53 2,44 Total liabilities 3,53 2,44 Total liabilities 1,755 2,130 Total liabilities 3,24 3,318 <th< td=""><td>Inventories</td><td>16,784</td><td>17,099</td></th<>	Inventories	16,784	17,099
Total current assets 32,187 34,210 Non-current assets 257 295 Property, plant and equipment 2,866 2,995 Deferred tax assets 7,373 7,473 Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 353 244 Total liabilities 35,318 35,188 Reserves 32,414 33,187 Equity 35,188 35,188 <t< td=""><td>Current tax assets</td><td>24</td><td>26</td></t<>	Current tax assets	24	26
Non-current assets 257 295 Property, plant and equipment 2,866 2,995 Deferred tax assets 7,373 7,473 Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 15,269 16,261 Non-current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 1,755 2,130 Total non-current liabilities 1,755 2,130 Total liabilities 1,755 2,130 Total liabilities 32,414 33,187 Equity 18,391 35,188 Reserves (1,076) 227 <	Other assets	742	848
Trade and other receivables 257 295 Property, plant and equipment 2,866 2,995 Deferred tax assets 7,373 7,473 Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Trade and other payables 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 1,755 2,130 Net assets 32,414 33,187 Equity 5,188 35,188	Total current assets	32,187	34,210
Property, plant and equipment 2,866 2,995 Deferred tax assets 7,373 7,473 Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 11,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 1,755 2,130 Total liabilities 35,318 35,188 Reserves (1,076) 227 Accumulated losses (1,076) 227 Accumulated losses (1,861) (2,379) <tr< td=""><td>Non-current assets</td><td></td><td></td></tr<>	Non-current assets		
Deferred tax assets 7,373 7,473 Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity 8 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 33,251 33,036	Trade and other receivables	257	295
Other intangible assets 720 704 Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities Trade and other payables 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Other liabilities 1,7024 18,391 Net assets 32,414 33,187 Equity Issued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151 <td>Property, plant and equipment</td> <td>2,866</td> <td>2,995</td>	Property, plant and equipment	2,866	2,995
Capitalised development expenditure 6,035 5,901 Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total non-current liabilities 1,755 2,130 Total liabilities 1,7024 18,391 Net assets 32,414 33,187 Equity 5,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Deferred tax assets	7,373	7,473
Total non-current assets 17,251 17,368 Total assets 49,438 51,578 Current liabilities	Other intangible assets	720	704
Total assets 49,438 51,578 Current liabilities Trade and other payables 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity 8 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,076) 227 Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Capitalised development expenditure	6,035	5,901
Current liabilities Trade and other payables 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity Issued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Total non-current assets	17,251	17,368
Trade and other payables 5,376 5,903 Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity Issued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Total assets	49,438	51,578
Borrowings 7,683 7,814 Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity Issued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Current liabilities		
Provisions 1,911 1,941 Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 200 1,184 1,654 Provisions 218 232 232 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244 232 244	Trade and other payables	5,376	5,903
Other liabilities 299 603 Total current liabilities 15,269 16,261 Non-current liabilities 8 8 Borrowings 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity Issued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Borrowings	7,683	7,814
Total current liabilities Non-current liabilities 1,184 1,654 Borrowings 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity 15 15 Issued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Provisions	1,911	1,941
Non-current liabilities In the second of the s	Other liabilities	299	603
Borrowings 1,184 1,654 Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity (1,076) 227 Accumulated losses (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Total current liabilities	15,269	16,261
Provisions 218 232 Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity 5 5,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Non-current liabilities		
Other liabilities 353 244 Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity 5 1,076 227 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Borrowings	1,184	1,654
Total non-current liabilities 1,755 2,130 Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity 5 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Provisions	218	232
Total liabilities 17,024 18,391 Net assets 32,414 33,187 Equity Susued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Other liabilities	353	244
Net assets 32,414 33,187 Equity 35,188 35,188 Issued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Total non-current liabilities	1,755	2,130
Equity Issued capital 35,188 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Total liabilities	17,024	18,391
Issued capital 35,188 35,188 Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Net assets	32,414	33,187
Reserves (1,076) 227 Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Equity		
Accumulated losses (1,861) (2,379) Parent entity interest 32,251 33,036 Non-controlling interest 163 151		35,188	35,188
Parent entity interest 32,251 33,036 Non-controlling interest 163 151	Reserves	(1,076)	227
Non-controlling interest 163 151	Accumulated losses	(1,861)	(2,379)
Non-controlling interest 163 151	Parent entity interest	32,251	33,036
Total equity 32,414 33,187		163	151
	Total equity	32,414	33,187

Consolidated statement of changes in equity for the half-year ended 31 December 2010

	Issued Capital \$'000	Share Option Reserve \$'000	Foreign Currency Reserve \$'000	Non- Controlling Interest \$'000	Accumu- lated Losses \$'000	Total \$'000
Balance at 1 July 2009 Total comprehensive income for the period Shares issued during the period	35,176 - 12	16 - -	847 (977) -	211 32 -	(6,199) 1,197 -	30,051 252 12
Subtotal Dividends paid or provided for	35,188 -	16 -	(130) -	243 -	(5,002)	30,315
Balance at 31 December 2009	35,188	16	(130)	243	(5,002)	30,315
Balance at 1 July 2010 Total comprehensive income for the period Subtotal	35,188 - 35,188	16 (16)	211 (1,287) (1,076)	151 12 163	(2,379) 518 (1,861)	33,187 (773) 32,414
Dividends paid or provided for	-	-	(1,076)	-	(1,601)	-
Balance at 31 December 2010	35,188	-	(1,076)	163	(1,861)	32,414

Consolidated statement of cash flows for the half-year ended 31 December 2010

Consolidated Group

Grant income received - 294 Payments to suppliers and employees (22,115) (24,734 Interest and other costs of finance paid (189) (204 Income tax refund - 416 Income tax paid (23) - Net cash provided by operating activities 1,810 2,919 Cash flows from investing activities 18 11 Interest received 18 11 Refund / (Payment) for deposits - (51 Payment for property, plant and equipment (212) (188 Payment for intangible assets (36) (104 Payment for business acquisitions - (724 Payment for capitalised development costs (686) (944 Net cash used in investing activities (916) (1,997 Cash flows from financing activities 696 1,925 Repayment of borrowings 696 1,925 Repayment of borrowings (1,297) (726		Half-year ended 31 Dec 2010	Half-year ended 31 Dec 2009
Receipts from customers 24,137 27,147 Grant income received - 294 Payments to suppliers and employees (22,115) (24,734 Interest and other costs of finance paid (189) (204 Income tax refund - 416 Income tax paid (23) - Net cash provided by operating activities 1,810 2,919 Cash flows from investing activities 18 11 Refund / (Payment) for deposits - (51 Payment for property, plant and equipment (212) (185 Payment for intangible assets (36) (104 Payment for business acquisitions - (724 Payment for capitalised development costs (686) (944 Net cash used in investing activities (916) (1,997 Cash flows from financing activities 696 1,925 Repayment of borrowings 696 1,925 Repayment of borrowings (1,297) (726		\$'000	\$'000
Grant income received - 294 Payments to suppliers and employees (22,115) (24,734 Interest and other costs of finance paid (189) (204 Income tax refund - 416 Income tax paid (23) - Net cash provided by operating activities 1,810 2,919 Cash flows from investing activities 18 11 Interest received 18 11 Refund / (Payment) for deposits - (51 Payment for property, plant and equipment (212) (188 Payment for intangible assets (36) (104 Payment for business acquisitions - (724 Payment for capitalised development costs (686) (944 Net cash used in investing activities (916) (1,997 Cash flows from financing activities 696 1,925 Repayment of borrowings 696 1,925 Repayment of borrowings (1,297) (726	Cash flows from operating activities		
Payments to suppliers and employees (22,115) (24,734 Interest and other costs of finance paid (189) (204 Income tax refund - 416 Income tax paid (23) - Net cash provided by operating activities 1,810 2,919 Cash flows from investing activities 1 1 Interest received 18 11 Refund / (Payment) for deposits - (51 Payment for property, plant and equipment (212) (188 Payment for business acquisitions - (724 Payment for capitalised development costs (686) (944 Net cash used in investing activities (916) (1,997 Cash flows from financing activities 696 1,925 Repayment of borrowings 696 1,925 Repayment of borrowings (1,297) (726	·	24,137	27,147
Interest and other costs of finance paid (189) (204 Income tax refund - 416 Income tax paid (23) Net cash provided by operating activities 1,810 2,919 Cash flows from investing activities Interest received 18 11 Refund / (Payment) for deposits - (51 Payment for property, plant and equipment (212) (185 Payment for intangible assets (36) (104 Payment for capitalised development costs (686) (944 Net cash used in investing activities (916) (1,997 Cash flows from financing activities 696 1,925 Repayment of borrowings 696 1,925 Repayment of borrowings (1,297) (726 Cash flows from financing activities (1,297) (1,297 Cash flows from financing activities (1,297 Cash flows from financing activities (1,297 Cash flows from financing activities (1,297 Cash fl		- <u>-</u> _	294
Income tax refund		_ , , , ,	, , ,
Income tax paid (23) Net cash provided by operating activities 1,810 2,919 Cash flows from investing activities Interest received 18 11 Refund / (Payment) for deposits - (51 Payment for property, plant and equipment (212) (185 Payment for intangible assets (36) (104 Payment for business acquisitions - (724 Payment for capitalised development costs (686) (944 Net cash used in investing activities (916) (1,997) Cash flows from financing activities Proceeds from borrowings 696 1,925 Repayment of borrowings (1,297) (726)	·	(189)	, ,
Net cash provided by operating activities Cash flows from investing activities Interest received Int		(23)	416
Interest received Refund / (Payment) for deposits Payment for property, plant and equipment Payment for intangible assets Payment for business acquisitions Payment for capitalised development costs Net cash used in investing activities Cash flows from financing activities Proceeds from borrowings Repayment of borrowings Repayment of borrowings 18 11 12 12 12 12 12 12 12 12 12 12 12 12			2,919
Interest received Refund / (Payment) for deposits Payment for property, plant and equipment Payment for intangible assets Payment for business acquisitions Payment for capitalised development costs Net cash used in investing activities Cash flows from financing activities Proceeds from borrowings Repayment of borrowings Repayment of borrowings 18 11 12 12 12 12 12 12 12 12 12 12 12 12			_
Refund / (Payment) for deposits Payment for property, plant and equipment Payment for intangible assets Payment for business acquisitions Payment for capitalised development costs Net cash used in investing activities Cash flows from financing activities Proceeds from borrowings Repayment of borrowings Repayment of borrowings - (51 (51 (51 (51 (51 (51 (51 (51 (51 (51	Cash flows from investing activities		
Payment for property, plant and equipment Payment for intangible assets Payment for business acquisitions Payment for capitalised development costs Net cash used in investing activities Cash flows from financing activities Proceeds from borrowings Repayment of borrowings (212) (185 (104 (104 (104 (105 (105 (105 (105 (105 (105 (105 (105	Interest received	18	11
Payment for intangible assets Payment for business acquisitions Payment for capitalised development costs Net cash used in investing activities Cash flows from financing activities Proceeds from borrowings Repayment of borrowings (36) (104 (724 (944) (916) (1,997) (1,297) (726)	Refund / (Payment) for deposits	-	(51)
Payment for business acquisitions Payment for capitalised development costs Net cash used in investing activities Cash flows from financing activities Proceeds from borrowings Repayment of borrowings (1,297) (726)		_ ` ' _	(185)
Payment for capitalised development costs (686) (944) Net cash used in investing activities (916) (1,997) Cash flows from financing activities Proceeds from borrowings 696 1,925 Repayment of borrowings (1,297) (726)	•	(36)	(104)
Net cash used in investing activities Cash flows from financing activities Proceeds from borrowings Repayment of borrowings (916) (1,997) 696 1,925 (1,297) (726)	·	- ()	(724)
Cash flows from financing activities Proceeds from borrowings 696 1,925 Repayment of borrowings (1,297) (726	Payment for capitalised development costs	(686)	(944)
Proceeds from borrowings 696 1,925 Repayment of borrowings (1,297) (726)	Net cash used in investing activities	(916)	(1,997)
Proceeds from borrowings 696 1,925 Repayment of borrowings (1,297) (726)	Cash flows from financing activities		
Repayment of borrowings (1,297) (726	-	696	1 925
Net cash (used in)/provided by financing activities (601) 1,199	•		(726)
	Net cash (used in)/provided by financing activities	(601)	1,199
	· · · · · · · · · · · · · · · · · · ·		2,121
	, and the second	3,217	1,601
Effects of exchange rate changes on the balance of cash held in foreign currencies (111) (337)		(111)	(337)
Cash and cash equivalents at the end of the period 3,399 3,385	Cash and cash equivalents at the end of the period	3,399	3,385

Notes to the Consolidated financial statements for the half-year ended 31 December 2010

Notes to the Consolidated financial statements for the half-year ended 31 December 2010

Note 1: Basis of preparation

These general purpose financial statements for the interim half-year reporting period ended 31 December 2010 have been prepared in accordance with requirements of the Corporations Act 2001 and Australian Accounting Standards including AASB 134: Interim Financial Reporting. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Ellex Medical Lasers Limited and its controlled entities (the Group). As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 30 June 2010, together with any public announcements made during the half-year.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements.

Borrowings

There has been a breach of the Debt Service Cover covenant (subsequently acknowledged and formally waived by the finance provider) during the period causing all finance facility debt to be classified as current.

Note 2: Operating Segments

(i) Segment performance

(i) Segment performance			
	Distributors \$'000	Direct \$'000	Total \$'000
Six months ended 31 December 2010 Revenue			
External sales	5,999	16,356	22,355
Total segment revenue	5,999	16,356	22,355
Segment net profit before tax	1,192	2,786	3,978
Reconciliation of segment result to group net profit/(loss) before tax Amounts not included in segment result but reviewed by the Board: Depreciation and amortisation Unallocated items:			(913)
Corporate charges			(2,258)
Finance costs			(189)
Interest revenue		_	17
Net profit before tax from continuing operations		_	635
Six months ended 31 December 2009 Revenue		_	
External sales	6,546	18,923	25,469
Total segment revenue	6,546	18,923	25,469
Segment net profit before tax	1,487	3,347	4,834

Ellex Medical Lasers Limited

Notes to the Consolidated financial statements for the half-year ended 31 December 2010

	Distributors \$'000	Direct \$'000	Total \$'000
Reconciliation of segment result to group net profit/(loss) before tax Amounts not included in segment result but reviewed by the Board: Depreciation and amortisation			(919)
 Unallocated items: Corporate charges Finance costs Other income 			(2,402) (204) 414 12
Interest revenue Net profit before tax from continuing operations		_	1,735
(ii) Segment assets	Distributors \$'000	Direct \$'000	Total \$'000
31 December 2010 Segment assets Segment asset increases for the period: Capital expenditure	10,881	26,541 31	37,422 42
• Other	(577)	(1,577)	(2,154)
Total segment assets	10,315	24,995	35,310
Reconciliation of segment assets to group assets Inter-segment eliminations Unallocated assets: Deferred tax assets Capitalised development expenditure Intangibles			7,373 6,035 720
Total group assets		_	49,438
30 June 2010 Segment assets Segment asset increases for the period:	10,497	26,281	36,778
Capital expenditure	384	260	644
Total segment assets	10,881	26,541	37,422
Reconciliation of segment assets to group assets Unallocated assets: Deferred tax assets Capitalised development expenditure Intangibles Others Total group assets		_ _	7,473 5,901 704 78 51,578



Level 1, 67 Greenhill Rd Wayville SA 5034 GPO Box 1270 Adelaide SA 5001

T 61 8 8372 6666 F 61 8 8372 6677 E info.sa@au.gt.com W www.grantthomton.com.au

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF ELLEX MEDICAL LASERS LIMITED AND CONTROLLED ENTITIES

We have reviewed the accompanying half-year financial report of Ellex Medical Lasers Limited ("Company"), which comprises the consolidated financial statements being the statement of financial position as at 31 December 2010, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, a statement of accounting policies, other selected explanatory notes and the directors' declaration of the consolidated entity, comprising both the Company and the entities it controlled at the half-year's end or from time to time during the half-year.

Directors' responsibility for the half-year financial report

The directors of the Company are responsible for the preparation and fair presentation of the half-year financial report in accordance with Australian Accounting Standards (including the Australian Accounting Interpretations) and the Corporations Act 2001. This responsibility includes establishing and maintaining internal controls relevant to the preparation and fair presentation of the half-year financial report that is free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's responsibility

Our responsibility is to express a conclusion on the consolidated half-year financial report based on our review. We conducted our review in accordance with the Auditing Standard on Review Engagements ASRE 2410: Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the consolidated entity's financial position as at 31 December 2010 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001.

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

Grant Thornton Australia Limited is a member firm within Grant Thornton International Ltd. Grant Thornton International Ltd and the member firms are not a worldwide partnership. Grant Thornton Australia Limited, together with its subsidiaries and related entities, delivers its services independently in Australia.



As the auditor of Ellex Medical Lasers Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Ellex Medical Lasers Limited and controlled entities is not in accordance with the Corporations Act 2001, including:

- a giving a true and fair view of the consolidated entity's financial position as at 31 December 2010 and of its performance for the half-year ended on that date; and
- b complying with Accounting Standard AASB 134: Interim Financial Reporting and Corporations Regulations 2001.

GRANT THORNTON AUDIT PTY LTD

Grant Tlanston.

Chartered Accountants

S J Gray

Director – Audit & Assurance Services

Corporate Directory

Directors

Mr Victor Previn BE (Chairman)

Mr Alex Sundich BEc, MComm, ACA, ASIA (Non-Executive Director)

Professor John Marshall Ph. D (Non-Executive Director)

Mr Giuseppe Canala BTECH, BA, FAICD (Non-Executive Director)

Mr Malcolm Plunkett (Executive Director)

Company Secretary

Mr Giuseppe Canala

Registered Office

Ellex Medical Lasers Limited ABN 15 007 702 927 82 Gilbert Street

Adelaide South Australia 5000 Telephone: +61 8 8104 5200 Facsimile: +61 8 8104 5231

Auditors

Grant Thornton Audit Pty Limited Level 1, 67 Greenhill Road Wayville South Australia 5034

Legal Advisors

Thomsons Lawyers Level 7, 19 Gouger Street Adelaide South Australia 5000

Share Registry

Computershare Investor Services Limited Level 5, 115 Grenfell Street Adelaide South Australia 5000

GPO Box 1903

Adelaide South Australia 5001

Enquiries within Australia: 1300 556 161 Enquiries outside Australia: +61 3 9415 4000

Website: www.computershare.com

Websites:

www.ellex.com www.slt-ellex.com

Stock Exchange

The company Ellex Medical Lasers Limited is listed on the Australian Securities Exchange (ASX). The ASX Code is: ELX-Ordinary Shares.